Car T Global Week
ARTIFICIAL INTELLIGENCE, DIAGNOSIS, AND IMAGING
Join strategic leaders to tackle the biggest obstacles in CAR T development. Have an opportunity to connect with key decision makers and multiple stakeholders in CAR T Cell Therapies. Starting with discovery and early stage strategies, participants traverse the current landscape including translation, clinical trials, manufacturing, and global markets.
Interactive group discussions with dedicated Q&A sessions will look at:
Breaking Through with Car T Therapies for Broader Cancer Indications
Novel Gene Editing Strategies for Enhancing Car T Cell Function
Clinical Trials
Furthering Clinical Efficacy in the Solid Tumor Space
The Global Regulatory & Commercial Landscape for Car-T
This year, take part in a pre-forum day of workshops and virtual simulations covering:
Investigational New Drug (IND) Submission Readiness
Virtual Pre-Approval Inspection Simulation with FDA Investigators
January 25-27, 2021
Live Virtual Forum (EST)
Pre-forum virtual workshops have a registration fee of $199
Vendor Delegates: $550
Latest News
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
LEARN MOREPfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
LEARN MOREJanux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
LEARN MORE